Zoetis stock drops despite market gains, but projected earnings and revenue growth are positive

From Nasdaq: 2024-07-26 18:15:18

In the latest trading session, Zoetis (ZTS) closed at $179.84, down 0.51%. This performance lagged behind the S&P 500’s 1.11% gain. Zoetis had a 2.44% gain in the past month, while the Medical sector and S&P 500 experienced losses.

Zoetis is set to report earnings on August 6, 2024, with projected earnings of $1.49 per share and revenue of $2.3 billion, indicating growth. Analysts expect full-year earnings of $5.76 per share and revenue of $9.13 billion, with positive changes in estimates reflecting optimism.

Despite recent estimate revisions, Zoetis maintains a Zacks Rank of #4 (Sell) and a Forward P/E ratio of 31.39. The PEG ratio is 2.81, higher than the industry average of 1.52. The Medical – Drugs industry ranks 96 out of over 250 industries.

For potential stock gains, analysts suggest keeping an eye on Zoetis. Free report: 5 “Whisper” Stocks Poised to Stun Wall Street with potential +10-20% jumps post-earnings. Explore investment opportunities and Zacks Investment Research recommendations for insights on market movements.



Read more at Nasdaq: Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note